# Teleflex Inc: overview

TFX · NYSE · CIK 96943 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tfx.md) · [Financials](/companies/tfx/financials.md) · [Filings](/companies/tfx/filings.md) · [Insiders](/companies/tfx/insiders.md)

Latest reported revenue: [$570.3m](/filings/0000096943-26-000095.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000096943-26-000095).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [426](/filings/0000096943-26-000019.md) | [442](/filings/0000096943-26-000019.md) | [414](/filings/0000096943-26-000050.md) | [443](/filings/0000096943-26-000095.md) | [567](/filings/0000096943-26-000019.md) | [569](/filings/0000096943-26-000019.md) | [548](/filings/0000096943-26-000050.md) | [570](/filings/0000096943-26-000095.md) |
| Gross margin | % | [61.1%](/filings/0000096943-26-000019.md) | [60.8%](/filings/0000096943-26-000019.md) | [61.7%](/filings/0000096943-26-000050.md) | [60.1%](/filings/0000096943-26-000095.md) | [51.5%](/filings/0000096943-26-000019.md) | [54.0%](/filings/0000096943-26-000019.md) | [56.1%](/filings/0000096943-26-000050.md) | [58.2%](/filings/0000096943-26-000095.md) |
| Operating margin | % | [16.9%](/filings/0000096943-26-000019.md) | [11.9%](/filings/0000096943-26-000019.md) | [18.3%](/filings/0000096943-26-000050.md) | [20.6%](/filings/0000096943-26-000095.md) | [(11.0%)](/filings/0000096943-26-000019.md) | [2.4%](/filings/0000096943-26-000019.md) | [3.7%](/filings/0000096943-26-000050.md) | [12.8%](/filings/0000096943-26-000095.md) |
| Net margin | % | [26.0%](/filings/0000096943-26-000019.md) | [(30.9%)](/filings/0000096943-26-000019.md) | [22.9%](/filings/0000096943-26-000095.md) | [27.7%](/filings/0000096943-26-000095.md) | [(72.1%)](/filings/0000096943-26-000019.md) | [(125.5%)](/filings/0000096943-26-000019.md) | [(1.5%)](/filings/0000096943-26-000095.md) | [17.5%](/filings/0000096943-26-000095.md) |
| Diluted EPS | $ per share | [2.36](/filings/0000096943-26-000019.md) | [(2.93)](/filings/0000096943-26-000019.md) | [2.07](/filings/0000096943-26-000050.md) | [2.77](/filings/0000096943-26-000095.md) | [(9.24)](/filings/0000096943-26-000019.md) | [(16.15)](/filings/0000096943-26-000019.md) | [(0.18)](/filings/0000096943-26-000050.md) | [2.28](/filings/0000096943-26-000095.md) |
| Free cash flow | $m | [210 d](/filings/0000096943-25-000138.md) | [(138) d](/filings/0000096943-26-000019.md) | [3.6](/filings/0000096943-26-000050.md) | [(64.8) d](/filings/0000096943-26-000095.md) | [156 d](/filings/0000096943-25-000138.md) | [(92.9) d](/filings/0000096943-26-000019.md) | [27.9](/filings/0000096943-26-000050.md) | [77.9 d](/filings/0000096943-26-000095.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,810](/filings/0000096943-24-000036.md) | [2,791](/filings/0000096943-25-000031.md) | [1,712](/filings/0000096943-26-000019.md) | [1,700](/filings/0000096943-26-000019.md) | [1,993](/filings/0000096943-26-000019.md) |
| Gross margin | % | [55.2%](/filings/0000096943-24-000036.md) | [54.9%](/filings/0000096943-25-000031.md) | [60.7%](/filings/0000096943-26-000019.md) | [61.0%](/filings/0000096943-26-000019.md) | [56.2%](/filings/0000096943-26-000019.md) |
| Operating margin | % | [22.4%](/filings/0000096943-24-000036.md) | [17.9%](/filings/0000096943-25-000031.md) | [15.1%](/filings/0000096943-26-000019.md) | [6.1%](/filings/0000096943-26-000019.md) | [5.9%](/filings/0000096943-26-000019.md) |
| Net margin | % | [17.3%](/filings/0000096943-24-000036.md) | [13.0%](/filings/0000096943-25-000031.md) | [20.8%](/filings/0000096943-26-000019.md) | [4.1%](/filings/0000096943-26-000019.md) | [(45.4%)](/filings/0000096943-26-000019.md) |
| Diluted EPS | $ per share | [10.23](/filings/0000096943-24-000036.md) | [7.68](/filings/0000096943-25-000031.md) | [7.53](/filings/0000096943-26-000019.md) | [1.48](/filings/0000096943-26-000019.md) | [(20.25)](/filings/0000096943-26-000019.md) |
| Free cash flow | $m | [581](/filings/0000096943-24-000036.md) | [264](/filings/0000096943-25-000031.md) | [160](/filings/0000096943-26-000019.md) | [211](/filings/0000096943-26-000019.md) | [1.4](/filings/0000096943-26-000019.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tfx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $688.5m | 5,431,818 |  | Added +39,827 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $550.5m | 4,342,512 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $513.3m | 4,291,311 |  | Not compared |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $306.4m | 2,416,998 |  | Reduced −21,185 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $253.0m | 1,995,717 |  | Added +11,893 |
| [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $193.5m | 1,526,228 |  | Unchanged |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $188.1m | 1,484,039 |  | Reduced −18,818 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $182.8m | 1,442,103 |  | Added +760,045 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $167.4m | 1,320,946 |  | Reduced −43,004 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $146.1m | 1,152,695 |  | Added +155,551 |

## Recent filings

[All 1,246 filings](/companies/tfx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-09 | 17:41 ET | [8-K](/filings/0000096943-26-000101.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000096943-26-000101 |
| 2026-08-07 | 16:43 ET | [8-K](/filings/0000096943-26-000097.md) | 8.01 Other events | 0000096943-26-000097 |
| 2026-08-06 | 15:08 ET | [10-Q](/filings/0000096943-26-000095.md) | Quarterly report, period 2026-06-30 | 0000096943-26-000095 |
| 2026-08-06 | 07:08 ET | [8-K](/filings/0000096943-26-000091.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000096943-26-000091 |
| 2026-08-05 | 16:44 ET | [8-K/A](/filings/0000096943-26-000087.md) | 9.01 Financial statements and exhibits | 0000096943-26-000087 |
| 2026-08-03 | 16:35 ET | [8-K](/filings/0000096943-26-000084.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000096943-26-000084 |
| 2026-06-15 | 17:24 ET | [8-K](/filings/0001193125-26-271318.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-271318 |
| 2026-06-09 | 17:13 ET | [8-K](/filings/0000096943-26-000072.md) | 5.02 Departure or appointment of officers or directors | 0000096943-26-000072 |
| 2026-06-02 | 18:35 ET | [8-K](/filings/0001193125-26-251951.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-251951 |
| 2026-06-01 | 07:59 ET | [8-K](/filings/0001193125-26-249764.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-249764 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000096943-26-000019.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3ea4f5ca-4565-4352-9099-cd615abcb6ce)

## About the filer

- CIK: 96943
- Tickers: TFX
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.